Sponsor content
24 result(s) found, displaying 1 to 10
-
Jul-2025Prescription medicine evaluationActive ingredient: axatilimab.
-
Jun-2025Prescription medicine evaluationActive ingredient: retifanlimab.
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Apr-2025Prescription medicine evaluationActive ingredient: tafasitamab.
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Designation or determinationOrphan drug
-
Designation or determinationOrphan Drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MINJUVI tafasitamab 200 mg powder for solution for infusion 1 vial per carton.